Y Chromosome Loss in Aging Men May Signal Cancer Before Tumors Form

One of the most common genetic changes in the aging male body has long been dismissed as a harmless byproduct of growing older. Now a study initiated at the University of Arizona Cancer Center suggests it may be anything but harmless. The research, published in JCI Insight and led by physician-scientist Dr. Dan Theodorescu, demonstrates that the gradual disappearance of the Y chromosome from a man’s cells is not confined to the blood, where it had been studied before, but spreads across ordinary tissue in patterns that track closely with the earliest stages of cancer formation. In men whose tissue appears entirely healthy under the microscope, the loss of this single chromosome may be quietly marking out zones where tumors are most likely to arise.

Every cell in a man’s body normally carries one X chromosome and one Y chromosome. The phenomenon known as loss of Y, sometimes called mosaic loss of the Y chromosome, occurs when individual cells drop their Y chromosome as they divide over the course of a lifetime. Previous studies established that this change is widespread in men as they age and that when it occurs in immune cells circulating in the blood it is associated with elevated risk of a range of diseases. What remained unknown was whether the same process was happening in solid organs, and if so, whether it had any relationship to the development of cancer in those organs.

The new study set out to answer that question systematically. Rather than looking at a single tissue type, the research team profiled Y chromosome loss across normal, precancerous and malignant tissue drawn from 11 major human organs. The scale of the effort was considerable. The investigators analyzed 1,000 tissue samples from 405 men and used an automated fluorescent imaging system to inspect more than 4.3 million individual cell nuclei. By measuring the ratio of Y to X chromosomes in each nucleus, they could quantify precisely how much of the chromosome had been lost in every region of tissue they examined.

The most striking findings came from a portion of the study focused on bladder tissue removed during cancer surgery. The researchers built detailed maps of these surgical specimens, charting exactly where Y chromosome loss appeared across each sample. The maps revealed a clear spatial pattern. Y chromosome loss increased progressively as the tissue moved from visibly normal bladder lining, through early abnormal cells, and finally into full-blown cancer. The change behaved like a slope that grows steadily steeper, rising in intensity with every step toward malignancy.

That gradient extended beyond the bladder. When the team compared normal-appearing tissue adjacent to tumors across different organs, they found the highest levels of Y chromosome loss in tissue surrounding cancers of the colon, rectum, esophagus, pancreas and lung. In other words, the chromosome was disappearing most aggressively in the healthy-looking neighborhoods immediately surrounding tumors, even though those regions contained no cancer cells themselves. The observation points to what cancer biologists call a pre-neoplastic field effect, a hidden zone of genetic vulnerability within apparently normal tissue that provides fertile ground for a tumor to develop.

We were able to show that the loss of the Y chromosome is found in normal appearing tissues adjacent to a tumor, said Theodorescu, the paper’s senior author and holder of the Nancy C. and Craig M. Berge endowed chair for the director of the Cancer Center. That finding is what makes this discovery so exciting. It suggests we may be looking at one of the earliest signposts of cancer forming. The statement captures why the result has generated attention well beyond the field of cancer genetics: if Y chromosome loss marks tissue before tumors appear, it could serve as an early warning signal visible in ordinary biopsy material.

Theodorescu, who is also a professor at the University of Arizona College of Medicine in Tucson, described the pattern with a landscape metaphor. We are now thinking of this as a gradient, similar to a hillside that slowly gets steeper, he said. The closer the tissue is to a cancer, the more Y chromosome loss we see. That gradient could one day help doctors suspect trouble in biopsies that miss a smaller cancer. The clinical implication is significant. Pathologists currently assess biopsy samples for visible abnormalities, but a cancer can be missed if the needle or instrument samples only normal-appearing tissue. A measurable molecular signal, present even in that normal tissue, could alert clinicians that something malignant lies nearby.

The new findings also build on Theodorescu’s earlier work on the biology of Y chromosome loss inside tumors themselves. His previous research showed that when cancer cells lose their Y chromosome, they gain the ability to evade the immune system, an effect that helps explain why loss of the chromosome has been linked in earlier studies to increased mortality from carcinomas. Taken together, the two lines of research sketch a coherent arc. Loss of Y may first render normal tissue more permissive to malignant transformation, and then, once cancer has taken hold, help the tumor hide from the immune defenses that would otherwise destroy it. The chromosome, in this view, is not a passive passenger but a participant at multiple stages of the disease.

How exactly the loss of a single chromosome produces these effects remains an open question. The Y chromosome carries genes involved in immune signaling and cellular regulation, and its disappearance from cells in blood has been linked in prior research to inflammatory and age-related conditions. In solid tissue, the progressive gradient observed in this study suggests that the loss is not random noise but something tied to the local biology of a forming tumor, whether as a cause, a consequence, or both. Disentangling those possibilities is the next challenge for the field, and the pan-organ mapping approach used here provides a framework for pursuing it at scale.

The study was a collaborative effort involving first authors Arkadiusz Gertych and Dr. Huihui Ye, along with collaborators from Cedars-Sinai Medical Center, Fred Hutchinson Cancer Center, the University of Washington and the University of California San Francisco. The work was funded in part by the National Cancer Institute, a division of the National Institutes of Health, under award No. R35CA294022 to Theodorescu. The research was published in JCI Insight on September 8, 2026, under the title Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer, and the authors declared no conflicts of interest. For millions of aging men, the finding reframes a familiar genetic change as a potential early alarm, one that could eventually be read from a routine biopsy long before a tumor announces itself.

Subject of Research: Mosaic loss of the Y chromosome in normal tissue as an early indicator of cancer development in men.

Article Title: Loss of Y chromosome in men could be early warning sign of cancer

Article References: Loss of Y chromosome in men could be early warning sign of cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Y chromosome loss, cancer, mosaic loss of Y, bladder cancer, pre-neoplastic field effect, JCI Insight, University of Arizona Cancer Center, fluorescent imaging, aging genetics, tumor microenvironment, immune evasion, pan-organ mapping